Norge -
norsk -
Statens legemiddelverk
citalopram orion 10 mg
orion corporation orion pharma - citalopramhydrobromid - tablett, filmdrasjert - 10 mg
Norge -
norsk -
Statens legemiddelverk
citalopram orion 20 mg
orion corporation orion pharma - citalopramhydrobromid - tablett, filmdrasjert - 20 mg
Norge -
norsk -
Statens legemiddelverk
escitalopram bluefish 10 mg
bluefish pharmaceuticals ab - escitalopramoksalat - tablett, filmdrasjert - 10 mg
Norge -
norsk -
Statens legemiddelverk
escitalopram bluefish 5 mg
bluefish pharmaceuticals ab - escitalopramoksalat - tablett, filmdrasjert - 5 mg
Norge -
norsk -
Statens legemiddelverk
escitalopram bluefish 20 mg
bluefish pharmaceuticals ab - escitalopramoksalat - tablett, filmdrasjert - 20 mg
Norge -
norsk -
Statens legemiddelverk
temgesic 0.2 mg
eumedica pharmaceuticals gmbh - buprenorfinhydroklorid - sublingvaltablett - 0.2 mg
Norge -
norsk -
Statens legemiddelverk
temgesic 0.3 mg/ ml
eumedica pharmaceuticals gmbh - buprenorfinhydroklorid - injeksjonsvæske, oppløsning - 0.3 mg/ ml
Norge -
norsk -
Statens legemiddelverk
temgesic 0.4 mg
eumedica pharmaceuticals gmbh - buprenorfinhydroklorid - sublingvaltablett - 0.4 mg
Den europeiske union -
norsk -
EMA (European Medicines Agency)
heplisav b
dynavax gmbh - hepatitt b overflate antigen - hepatitt b - vaksiner - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations. it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.
Norge -
norsk -
Statens legemiddelverk
bunalict 8 mg / 2 mg
sandoz - københavn - buprenorfinhydroklorid / naloksonhydrokloriddihydrat - sublingvaltablett - 8 mg / 2 mg